Navigation Links
Bionovo Announces Decision to Explore Strategic Options and to Delay Announcement of Financial Results for 2011
Date:2/21/2012

EMERYVILLE, Calif., Feb. 21, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform:  BNVI.PK), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced its decision to explore strategic options.  As a result of this decision, the Company has decided to delay the announcement of its financial results for the year ended December 31, 2011, previously planned for today, to a later date.  The Company will provide an update for the release of its 2011 financial results within the next two weeks.

(Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO)

"We believe Menerba, our drug for the treatment of menopausal hot flashes currently in a Phase 3 trial, is a very valuable asset and we are focusing all of our efforts to complete that clinical trial," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "We are pursuing financial options to fund completion of the pivotal trial, but the outcome of those efforts cannot be assured.  We have therefore decided to explore in parallel, strategic options that may provide more value to our shareholders and ensure the continued development of Bionovo's products."

The Company has engaged Cowen and Company to assist Bionovo to explore its strategic options.

The Company will need to obtain substantial amounts of cash to achieve its objectives of internally developing drugs.  The Company does not currently have adequate internal liquidity to meet its cash needs in the near term including completion of the ongoing Phase 3 trial for Menerba.  If sufficient additional funds are not received in the near term, the Company may not be able to execute its business plan and may need to significantly curtail or cease operations.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the OTC Link Platform under the symbol, "BNVI.PK". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo to Host Conference Call to Discuss 2011 Highlights and Year-End Financial Results
2. Bionovo Announces Third Quarter 2011 Highlights and Financial Results
3. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
4. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
5. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
6. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
7. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
8. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
9. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
10. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
11. Bionovo Announces 2010 Highlights and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Market Analysis & Trends - Technology, Route Of Administration, End User ... ... Market is poised to grow at a CAGR of around 7.8% ... This industry report analyzes the global markets for ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, ... 2024" report to their offering. ... The global clinical laboratory testing market is ... of innovative solutions on the grounds of maximum efficiency and minimum ...
(Date:1/20/2017)... 20, 2017  Ethicon Endo-Surgery, Inc. announced ... Products, Inc., a privately held medical device ... tools used in operating rooms worldwide. The ... advanced energy devices with Megadyne,s innovative portfolio ... forward in Ethicon,s goal to deliver the ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... education and high-level training standards for healthcare treatment providers who treat the full ... its Presidents Council. , The Presidents Council consists of the leading eating ...
(Date:1/23/2017)... ... 23, 2017 , ... Zachary Cattell, President of the Indiana ... industry expert at the 2017 Sector Summit hosted by Ivy Tech Community College ... Gerry Dick, will feature an employer and an association representative from five of ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
(Date:1/23/2017)... (PRWEB) , ... January 23, ... ... Partnership (SNP) has launched online education programs and resources at seafoodnutrition.org/programs and ... nutritional benefits of a seafood-rich diet. These resources have been developed for ...
(Date:1/22/2017)... Boca Raton, FL (PRWEB) , ... January 22, 2017 , ... ... products to customers across the world, recently met with big-name retail buyers at the ... strong scientific evidence of efficacy and uses the utmost safety standards in all of ...
Breaking Medicine News(10 mins):